Appendix F:
Observational results: ischemic stroke

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
2	He 2002 12495393	Health Professional Follow-up Study	Stroke, ischemic	criteria of the national survey of stroke	Healthy	Healthy 40-75 yo men without diagnosis of myocardial infarction, angina, stroke, transient ischemic attack, or peripheral arterial disease, or had undergone coronary artery surgery.	Men	377/43671 (0.86)	12 y	EPA+DHA	Intake	No
3	He 2002 12495393	Health Professional Follow-up Study	Stroke, ischemic	criteria of the national survey of stroke	Healthy	Healthy 40-75 yo men without diagnosis of myocardial infarction, angina, stroke, transient ischemic attack, or peripheral arterial disease, or had undergone coronary artery surgery.	Men	377/43671 (0.86)	12 y	EPA+DHA	Intake	No
4	He 2002 12495393	Health Professional Follow-up Study	Stroke, ischemic	criteria of the national survey of stroke	Healthy	Healthy 40-75 yo men without diagnosis of myocardial infarction, angina, stroke, transient ischemic attack, or peripheral arterial disease, or had undergone coronary artery surgery.	Men	377/43671 (0.86)	12 y	EPA+DHA	Intake	No
5	He 2002 12495393	Health Professional Follow-up Study	Stroke, ischemic	criteria of the national survey of stroke	Healthy	Healthy 40-75 yo men without diagnosis of myocardial infarction, angina, stroke, transient ischemic attack, or peripheral arterial disease, or had undergone coronary artery surgery.	Men	377/43671 (0.86)	12 y	EPA+DHA	Intake	No
6	He 2002 12495393	Health Professional Follow-up Study	Stroke, ischemic	criteria of the national survey of stroke	Healthy	Healthy 40-75 yo men without diagnosis of myocardial infarction, angina, stroke, transient ischemic attack, or peripheral arterial disease, or had undergone coronary artery surgery.	Men	377/43671 (0.86)	12 y	EPA+DHA	Intake	No
7	Iso 2001 11176840	Nurses' Health Study	Stroke, ischemic		Healthy	Healthy 34-59 yo female nurses	Women	303/79839 (0.38)	14 y	EPA+DHA	Intake	no
8	Iso 2001 11176840	Nurses' Health Study	Stroke, ischemic		Healthy	Healthy 34-59 yo female nurses	Women	303/79839 (0.38)	14 y	EPA+DHA	Intake	no
9	Iso 2001 11176840	Nurses' Health Study	Stroke, ischemic		Healthy	Healthy 34-59 yo female nurses	Women	303/79839 (0.38)	14 y	EPA+DHA	Intake	no
10	Iso 2001 11176840	Nurses' Health Study	Stroke, ischemic		Healthy	Healthy 34-59 yo female nurses	Women	303/79839 (0.38)	14 y	EPA+DHA	Intake	no
11	Iso 2001 11176840	Nurses' Health Study	Stroke, ischemic		Healthy	Healthy 34-59 yo female nurses	Women	303/79839 (0.38)	14 y	EPA+DHA	Intake	no
12	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	All n-3	Plasma	no
13	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	All n-3	Plasma	no
14	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	All n-3	Plasma	no
15	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	All n-3	Plasma	no
16	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	All n-3	Plasma	no

Appendix F:
Observational results: ischemic stroke

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low
2	He 2002 12495393	BMI, physcial activity, hx hypertension, smoking status, aspirin use, fish oil, multivitamins, total calorie intake, total fat. Saturated fat, trans-unstaurated fat, alcohol, potassium, magnesium, total servings of fruits and vegatbles, and hypercholsterolemia at baseline.	Qt1	g/d	0
3	He 2002 12495393	BMI, physcial activity, hx hypertension, smoking status, aspirin use, fish oil, multivitamins, total calorie intake, total fat. Saturated fat, trans-unstaurated fat, alcohol, potassium, magnesium, total servings of fruits and vegatbles, and hypercholsterolemia at baseline.	Qt2	g/d	0.05
4	He 2002 12495393	BMI, physcial activity, hx hypertension, smoking status, aspirin use, fish oil, multivitamins, total calorie intake, total fat. Saturated fat, trans-unstaurated fat, alcohol, potassium, magnesium, total servings of fruits and vegatbles, and hypercholsterolemia at baseline.	Qt3	g/d	0.2
5	He 2002 12495393	BMI, physcial activity, hx hypertension, smoking status, aspirin use, fish oil, multivitamins, total calorie intake, total fat. Saturated fat, trans-unstaurated fat, alcohol, potassium, magnesium, total servings of fruits and vegatbles, and hypercholsterolemia at baseline.	Qt4	g/d	0.4
6	He 2002 12495393	BMI, physcial activity, hx hypertension, smoking status, aspirin use, fish oil, multivitamins, total calorie intake, total fat. Saturated fat, trans-unstaurated fat, alcohol, potassium, magnesium, total servings of fruits and vegatbles, and hypercholsterolemia at baseline.	Qt5	g/d	0.6
7	Iso 2001 11176840	joules (continuous), BMI, alcohol intake, menopausal status and postmenopausal hormone use, vigorous exercise, usual aspirin use, multivitamin use, history of HTN, frequency of total fruit and vegetable servings and for nutrient intake of saturated fat, trans-unsaturated fat, linoleic acid, animal protein, calcium	Qt1	g/d	nd
8	Iso 2001 11176840	joules (continuous), BMI, alcohol intake, menopausal status and postmenopausal hormone use, vigorous exercise, usual aspirin use, multivitamin use, history of HTN, frequency of total fruit and vegetable servings and for nutrient intake of saturated fat, trans-unsaturated fat, linoleic acid, animal protein, calcium	Qt2	g/d	nd
9	Iso 2001 11176840	joules (continuous), BMI, alcohol intake, menopausal status and postmenopausal hormone use, vigorous exercise, usual aspirin use, multivitamin use, history of HTN, frequency of total fruit and vegetable servings and for nutrient intake of saturated fat, trans-unsaturated fat, linoleic acid, animal protein, calcium	Qt3	g/d	nd
10	Iso 2001 11176840	joules (continuous), BMI, alcohol intake, menopausal status and postmenopausal hormone use, vigorous exercise, usual aspirin use, multivitamin use, history of HTN, frequency of total fruit and vegetable servings and for nutrient intake of saturated fat, trans-unsaturated fat, linoleic acid, animal protein, calcium	Qt4	g/d	nd
11	Iso 2001 11176840	joules (continuous), BMI, alcohol intake, menopausal status and postmenopausal hormone use, vigorous exercise, usual aspirin use, multivitamin use, history of HTN, frequency of total fruit and vegetable servings and for nutrient intake of saturated fat, trans-unsaturated fat, linoleic acid, animal protein, calcium	Qt5	g/d	nd
12	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt1	% FA	nd
13	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt2	% FA	nd
14	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt3	% FA	nd
15	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt4	% FA	nd
16	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt5	% FA	nd

Appendix F:
Observational results: ischemic stroke

Row	Study PMID	Quantile median	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
2	He 2002 12495393	nd	<0.05	RR	24	nd	19741	Reference group			p trend	0.73
3	He 2002 12495393	nd	<0.2	RR	112	nd	155579	0.56	0.35	0.88		
4	He 2002 12495393	nd	<0.4	RR	147	nd	175161	0.63	0.4	0.98		
5	He 2002 12495393	nd	<0.6	RR	51	nd	68003	0.54	0.32	0.91		
6	He 2002 12495393	nd	>=0.6	RR	43	nd	43539	0.73	0.43	1.25		
7	Iso 2001 11176840	0.077	nd	RR	72	nd	nd	Reference group			P trend	0.28
8	Iso 2001 11176840	0.118	nd	RR	61	nd	nd	0.83	0.59	1.18		
9	Iso 2001 11176840	0.171	nd	RR	51	nd	nd	0.67	0.47	0.98		
10	Iso 2001 11176840	0.221	nd	RR	63	nd	nd	0.82	0.57	1.18		
11	Iso 2001 11176840	0.481	nd	RR	56	nd	nd	0.71	0.46	1.1		
12	Mozaffarian 2013 23546563	3.17	nd	HR	nd	nd	nd	Reference group			P trend	0.043
13	Mozaffarian 2013 23546563	3.72	nd	HR	nd	nd	nd	0.88	0.63	1.23		
14	Mozaffarian 2013 23546563	4.21	nd	HR	nd	nd	nd	0.77	0.54	1.08		
15	Mozaffarian 2013 23546563	4.8	nd	HR	nd	nd	nd	0.93	0.66	1.31		
16	Mozaffarian 2013 23546563	6.04	nd	HR	nd	nd	nd	0.63	0.43	0.94		

Appendix F:
Observational results: ischemic stroke

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
17	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DHA	Plasma	no
18	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DHA	Plasma	no
19	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DHA	Plasma	no
20	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DHA	Plasma	no
21	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DHA	Plasma	no
22	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	EPA	Plasma	no
23	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	EPA	Plasma	no
24	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	EPA	Plasma	no
25	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	EPA	Plasma	no
26	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	EPA	Plasma	no
27	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	278/2583 (10.76)	12y	ALA	Intake	no
28	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	278/2583 (10.76)	12y	ALA	Intake	no
29	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	278/2583 (10.76)	12y	ALA	Intake	no
30	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	278/2583 (10.76)	12y	ALA	Intake	no
31	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	278/2583 (10.76)	12y	ALA	Intake	no
32	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	337/2709 (12.44)	16y	ALA	Plasma	no
33	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	337/2709 (12.44)	16y	ALA	Plasma	no
34	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	337/2709 (12.44)	16y	ALA	Plasma	no
35	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	337/2709 (12.44)	16y	ALA	Plasma	no
36	Fretts 2014 25159901	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	337/2709 (12.44)	16y	ALA	Plasma	no

Appendix F:
Observational results: ischemic stroke

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low
17	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt1	% FA	nd
18	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt2	% FA	nd
19	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt3	% FA	nd
20	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt4	% FA	nd
21	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt5	% FA	nd
22	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt1	% FA	nd
23	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt2	% FA	nd
24	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt3	% FA	nd
25	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt4	% FA	nd
26	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt5	% FA	nd
27	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt1	% fat intake	0.39
28	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt2	% fat intake	1.45
29	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt3	% fat intake	1.65
30	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt4	% fat intake	1.87
31	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt5	% fat intake	2.17
32	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt1	% FA	0.05
33	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt2	% FA	0.11
34	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt3	% FA	0.13
35	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt4	% FA	0.15
36	Fretts 2014 25159901	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt5	% FA	0.19

Row	Study PMID	Quantile median	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
17	Mozaffarian 2013 23546563	1.95	nd	HR	nd	nd	nd	Reference group			P trend	0.052
18	Mozaffarian 2013 23546563	2.44	nd	HR	nd	nd	nd	1.01	0.72	1.41		
19	Mozaffarian 2013 23546563	2.87	nd	HR	nd	nd	nd	1	0.72	1.4		
20	Mozaffarian 2013 23546563	3.36	nd	HR	nd	nd	nd	0.73	0.51	1.06		
21	Mozaffarian 2013 23546563	4.34	nd	HR	nd	nd	nd	0.74	0.5	1.1		
22	Mozaffarian 2013 23546563	0.3	nd	HR	nd	nd	nd	Reference group			P trend	0.74
23	Mozaffarian 2013 23546563	0.41	nd	HR	nd	nd	nd	0.99	0.7	1.41		
24	Mozaffarian 2013 23546563	0.51	nd	HR	nd	nd	nd	0.94	0.66	1.34		
25	Mozaffarian 2013 23546563	0.64	nd	HR	nd	nd	nd	0.83	0.58	1.2		
26	Mozaffarian 2013 23546563	0.92	nd	HR	nd	nd	nd	1.09	0.76	1.57		
27	Fretts 2014 25159901	1.33	1.45	HR	59	nd	4691	Reference group			P trend	0.29
28	Fretts 2014 25159901	1.56	1.65	HR	52	nd	4785	0.89	0.61	1.3		
29	Fretts 2014 25159901	1.76	1.87	HR	54	nd	4891	0.84	0.58	1.22		
30	Fretts 2014 25159901	2	2.17	HR	67	nd	4997	1.08	0.75	1.54		
31	Fretts 2014 25159901	2.44	4.88	HR	46	nd	5380	0.7	0.47	1.04		
32	Fretts 2014 25159901	0.09	0.11	HR	69	nd	6208	Reference group			P trend	0.72
33	Fretts 2014 25159901	0.12	0.13	HR	63	nd	5792	0.92	0.65	1.3		
34	Fretts 2014 25159901	0.14	0.15	HR	70	nd	6026	1.01	0.72	1.43		
35	Fretts 2014 25159901	0.17	0.19	HR	62	nd	6132	0.84	0.59	1.2		
36	Fretts 2014 25159901	0.22	0.47	HR	73	nd	6589	0.97	0.69	1.36		

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
37	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DPA	Plasma	no
38	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DPA	Plasma	no
39	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DPA	Plasma	no
40	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DPA	Plasma	no
41	Mozaffarian 2013 23546563	Cardiovascular Health Study	Stroke, ischemic		Healthy	Healthy age >= 65y	All	319/3941 (8.09)	16y	DPA	Plasma	no
42	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA+DHA+DPA	Cholesterol ester	Yes
43	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA+DHA+DPA	Cholesterol ester	Yes
44	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA+DHA+DPA	Cholesterol ester	Yes
45	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA+DHA+DPA	Cholesterol ester	Yes
46	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA+DHA+DPA	Phospholipid	Yes
47	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA+DHA+DPA	Phospholipid	Yes
48	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA+DHA+DPA	Phospholipid	Yes
49	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA+DHA+DPA	Phospholipid	Yes
50	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	ALA	Cholesterol ester	Yes
51	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	ALA	Cholesterol ester	Yes
52	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	ALA	Phospholipid	Yes
53	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	ALA	Phospholipid	Yes
54	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA	Cholesterol ester	Yes
55	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA	Cholesterol ester	Yes
56	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA	Phospholipid	Yes
57	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	EPA	Phospholipid	Yes
58	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	DHA	Cholesterol ester	Yes
59	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	DHA	Cholesterol ester	Yes

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low
37	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt1	% FA	nd
38	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt2	% FA	nd
39	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt3	% FA	nd
40	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt4	% FA	nd
41	Mozaffarian 2013 23546563	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt5	% FA	nd
42	Yamagishi 2013 23920478	adjusted for age, sex, smoking, cigerette-years and alcohol consumption	Qr1	% FA	0.22
43	Yamagishi 2013 23920478	adjusted for age, sex, smoking, cigerette-years and alcohol consumption	Qr2	% FA	0.78
44	Yamagishi 2013 23920478	adjusted for age, sex, smoking, cigerette-years and alcohol consumption	Qr3	% FA	0.94
45	Yamagishi 2013 23920478	adjusted for age, sex, smoking, cigerette-years and alcohol consumption	Qr4	% FA	1.15
46	Yamagishi 2013 23920478	adjusted for age, sex, smoking, cigerette-years and alcohol consumption	Qr1	% FA	1.51
47	Yamagishi 2013 23920478	adjusted for age, sex, smoking, cigerette-years and alcohol consumption	Qr2	% FA	3.58
48	Yamagishi 2013 23920478	adjusted for age, sex, smoking, cigerette-years and alcohol consumption	Qr3	% FA	4.12
49	Yamagishi 2013 23920478	adjusted for age, sex, smoking, cigerette-years and alcohol consumption	Qr4	% FA	4.75
50	Yamagishi 2013 23920478	adjusted for age and sex	Qt1	% FA	nd
51	Yamagishi 2013 23920478	adjusted for age and sex	Qt5	% FA	nd
52	Yamagishi 2013 23920478	adjusted for age and sex	Qt1	% FA	nd
53	Yamagishi 2013 23920478	adjusted for age and sex	Qt5	% FA	nd
54	Yamagishi 2013 23920478	adjusted for age and sex	Qt1	% FA	nd
55	Yamagishi 2013 23920478	adjusted for age and sex	Qt5	% FA	nd
56	Yamagishi 2013 23920478	adjusted for age and sex	Qt1	% FA	nd
57	Yamagishi 2013 23920478	adjusted for age and sex	Qt5	% FA	nd
58	Yamagishi 2013 23920478	adjusted for age and sex	Qt1	% FA	nd
59	Yamagishi 2013 23920478	adjusted for age and sex	Qt5	% FA	nd

Row	Study PMID	Quantile median	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
37	Mozaffarian 2013 23546563	0.63	nd	HR	nd	nd	nd	Reference group			P trend	0.22
38	Mozaffarian 2013 23546563	0.75	nd	HR	nd	nd	nd	0.77	0.55	1.08		
39	Mozaffarian 2013 23546563	0.82	nd	HR	nd	nd	nd	0.73	0.52	1.04		
40	Mozaffarian 2013 23546563	0.91	nd	HR	nd	nd	nd	0.78	0.56	1.1		
41	Mozaffarian 2013 23546563	1.04	nd	HR	nd	nd	nd	0.78	0.55	1.1		
42	Yamagishi 2013 23920478	nd	0.77	HR	nd	nd	nd	Reference group			P trend	0.52
43	Yamagishi 2013 23920478	nd	0.93	HR	nd	nd	nd	1.22	0.27	2		
44	Yamagishi 2013 23920478	nd	1.14	HR	nd	nd	nd	1.07	0.07	1.97		
45	Yamagishi 2013 23920478	nd	6.02	HR	nd	nd	nd	1.21	0.21	2.01		
46	Yamagishi 2013 23920478	nd	3.57	HR	nd	nd	nd	Reference group			P trend	0.51
47	Yamagishi 2013 23920478	nd	4.11	HR	nd	nd	nd	1.06	0.1]	1.96		
48	Yamagishi 2013 23920478	nd	4.74	HR	nd	nd	nd	0.8	-0.2	1.8		
49	Yamagishi 2013 23920478	nd	13.5	HR	nd	nd	nd	0.94	0.24	1.94		
50	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	Reference group			P trend	0.61
51	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	1.14	0.76	1.72		
52	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	Reference group			P trend	0.16
53	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	1.29	0.82	2.02		
54	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	Reference group			P trend	0.39
55	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	1.16	0.76	1.76		
56	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	Reference group			P trend	0.37
57	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	1.18	0.78	1.78		
58	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	Reference group			P trend	0.07
59	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	0.7	0.45	1.08		

Appendix F:
Observational results: ischemic stroke

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
60	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	DHA	Phospholipid	Yes
61	Yamagishi 2013 23920478	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of histrory of stroke and or transient ischemic attack	All	168/3870 (4.34)	22	DHA	Phospholipid	Yes
62	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA+DHA	Intake	Yes
63	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA+DHA	Intake	Yes
64	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA+DHA	Intake	Yes
65	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA+DHA	Intake	Yes
66	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	DHA	Intake	Yes
67	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	DHA	Intake	Yes
68	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	DHA	Intake	Yes
69	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	DHA	Intake	Yes
70	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA	Intake	Yes
71	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA	Intake	Yes
72	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA	Intake	Yes
73	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA	Intake	Yes
74	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA+DHA	Phospholipid	Yes
75	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA+DHA	Phospholipid	Yes
76	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA+DHA	Phospholipid	Yes
77	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA+DHA	Phospholipid	Yes
78	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	DHA	Phospholipid	Yes
79	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	DHA	Phospholipid	Yes
80	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	DHA	Phospholipid	Yes
81	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	DHA	Phospholipid	Yes

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low
60	Yamagishi 2013 23920478	adjusted for age and sex	Qt1	% FA	nd
61	Yamagishi 2013 23920478	adjusted for age and sex	Qt5	% FA	nd
62	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr1	% FA	nd
63	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr2	% FA	nd
64	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr3	% FA	nd
65	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr4	% FA	nd
66	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr1	% FA	nd
67	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr2	% FA	nd
68	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr3	% FA	nd
69	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr4	% FA	nd
70	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr1	% FA	nd
71	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr2	% FA	nd
72	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr3	% FA	nd
73	Gronroos 2012 22570739	adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr4	% FA	nd
74	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr1	% FA	nd
75	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr2	% FA	nd
76	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr3	% FA	nd
77	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr4	% FA	nd
78	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr1	% FA	nd
79	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr2	% FA	nd
80	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr3	% FA	nd
81	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr4	% FA	nd

Row	Study PMID	Quantile median	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
60	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	Reference group			P trend	0.08
61	Yamagishi 2013 23920478	nd	nd	HR	nd	nd	nd	0.69	0.46	1.06		
62	Gronroos 2012 22570739	nd	nd	HR	402	nd	61943	Reference group			P trend	0.21
63	Gronroos 2012 22570739	nd	nd	HR	427	nd	62339	1.04	0.9	1.2		
64	Gronroos 2012 22570739	nd	nd	HR	409	nd	62270	1.06	0.91	1.23		
65	Gronroos 2012 22570739	nd	nd	HR	366	nd	63223	0.92	0.79	1.07		
66	Gronroos 2012 22570739	nd	nd	HR	404	nd	61750	Reference group			P trend	0.21
67	Gronroos 2012 22570739	nd	nd	HR	428	nd	62584	1.06	0.92	1.23		
68	Gronroos 2012 22570739	nd	nd	HR	410	nd	62134	1.05	0.9	1.22		
69	Gronroos 2012 22570739	nd	nd	HR	362	nd	63307	0.93	0.8	1.09		
70	Gronroos 2012 22570739	nd	nd	HR	412	nd	61962	Reference group			P trend	0.22
71	Gronroos 2012 22570739	nd	nd	HR	418	nd	62298	1.05	0.91	1.22		
72	Gronroos 2012 22570739	nd	nd	HR	392	nd	62701	1	0.86	1.16		
73	Gronroos 2012 22570739	nd	nd	HR	382	nd	62815	0.93	0.8	1.08		
74	Gronroos 2012 22570739	nd	nd	HR	112	nd	16114	Reference group			P trend	0.54
75	Gronroos 2012 22570739	nd	nd	HR	95	nd	16994	0.8	0.6	1.06		
76	Gronroos 2012 22570739	nd	nd	HR	93	nd	16829	0.81	0.61	1.08		
77	Gronroos 2012 22570739	nd	nd	HR	101	nd	17144	0.87	0.66	1.15		
78	Gronroos 2012 22570739	nd	nd	HR	117	nd	16118	Reference group			P trend	0.47
79	Gronroos 2012 22570739	nd	nd	HR	86	nd	16961	0.71	0.54	0.95		
80	Gronroos 2012 22570739	nd	nd	HR	99	nd	16849	0.82	0.62	1.08		
81	Gronroos 2012 22570739	nd	nd	HR	99	nd	17153	0.84	0.63	1.11		

Appendix F:
Observational results: ischemic stroke

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
82	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA	Phospholipid	Yes
83	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA	Phospholipid	Yes
84	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA	Phospholipid	Yes
85	Gronroos 2012 22570739	Atherosclerosis Risk in Communities Study	Stroke, ischemic	ischemic stroke	Healthy	white aged 45-64 free of atrial fibrillation	All	400/3713 (10.77)	17.9	EPA	Phospholipid	Yes
86	de Goede 2013 22633188	MORGEN	Stroke, ischemic	ischemic stroke	Healthy	adults 20-65 yr	All	93/186 (50)	10.5 yr	ALA	Plasma	No
87	de Goede 2013 22633188	MORGEN	Stroke, ischemic	ischemic stroke	Healthy	adults 20-65 yr	All	93/186 (50)	10.5 yr	EPA+DHA	Plasma	No
88	de Goede 2011 21464993	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	All	144/19896 (0.72)	10.5 y	ALA	Intake	No
89	de Goede 2011 21464993	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	All	144/19896 (0.72)	10.5 y	ALA	Intake	No
90	de Goede 2011 21464993	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	All	144/19896 (0.72)	10.5 y	ALA	Intake	No
91	de Goede 2011 21464993	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	All	144/19896 (0.72)	10.5 y	ALA	Intake	No
92	de Goede 2011 21464993	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	All	144/19896 (0.72)	10.5 y	ALA	Intake	No
94	**Subgroup analyses**											
95	de Goede 2012 22496770	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	Women	nd/11081 (2.6 per 10,000 pt yrs)	10.5 y	EPA+DHA	Intake	No
96	de Goede 2012 22496770	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	Women	nd/11081 (2.6 per 10,000 pt yrs)	10.5 y	EPA+DHA	Intake	No
97	de Goede 2012 22496770	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	Women	nd/11081 (2.6 per 10,000 pt yrs)	10.5 y	EPA+DHA	Intake	No
98	de Goede 2012 22496770	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	Women	nd/11081 (2.6 per 10,000 pt yrs)	10.5 y	EPA+DHA	Intake	No
99	de Goede 2012 22496770	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	Men	nd/8988 (5.6 per 10,000 pt yrs)	10.5 y	EPA+DHA	Intake	No
100	de Goede 2012 22496770	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	Men	nd/8988 (5.6 per 10,000 pt yrs)	10.5 y	EPA+DHA	Intake	No
101	de Goede 2012 22496770	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	Men	nd/8988 (5.6 per 10,000 pt yrs)	10.5 y	EPA+DHA	Intake	No
102	de Goede 2012 22496770	MORGEN	Stroke, ischemic	Ischemic Stroke	Healthy	Healthy 20-65 yo	Men	nd/8988 (5.6 per 10,000 pt yrs)	10.5 y	EPA+DHA	Intake	No

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low
82	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr1	% FA	nd
83	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr2	% FA	nd
84	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr3	% FA	nd
85	Gronroos 2012 22570739	adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.	Qr4	% FA	nd
86	de Goede 2013 22633188	matched for age, gender, and enrollment data + smoking + BMI + education level + alcohol intake + diabetes + hypertension + hypercholesteroemia	all	% FA	nd
87	de Goede 2013 22633188	matched for age, gender, and enrollment data + smoking + BMI + education level + alcohol intake + diabetes + hypertension + hypercholesteroemia	all	% FA	nd
88	de Goede 2011 21464993	age, gender, BMI, total energy intake, cigarette smoking, education level, parental history of MI, alcohol intake, intake of vit C, beta-carotene, fiber, SFA, TFA, PUFA other than ALA	Qt1	g/d	nd
89	de Goede 2011 21464993	age, gender, BMI, total energy intake, cigarette smoking, education level, parental history of MI, alcohol intake, intake of vit C, beta-carotene, fiber, SFA, TFA, PUFA other than ALA	Qt2	g/d	nd
90	de Goede 2011 21464993	age, gender, BMI, total energy intake, cigarette smoking, education level, parental history of MI, alcohol intake, intake of vit C, beta-carotene, fiber, SFA, TFA, PUFA other than ALA	Qt3	g/d	nd
91	de Goede 2011 21464993	age, gender, BMI, total energy intake, cigarette smoking, education level, parental history of MI, alcohol intake, intake of vit C, beta-carotene, fiber, SFA, TFA, PUFA other than ALA	Qt4	g/d	nd
92	de Goede 2011 21464993	age, gender, BMI, total energy intake, cigarette smoking, education level, parental history of MI, alcohol intake, intake of vit C, beta-carotene, fiber, SFA, TFA, PUFA other than ALA	Qt5	g/d	nd
94	**Subgroup analyses**				
95	de Goede 2012 22496770	age, smoking, BMI, educational level, parental history of myocardial infarction, alcohol intake, total energy intake, dietary fiber, vit C, beta-careotene, SFA, TFA, MFA, LA, ALA	Qt1	mg/d	nd
96	de Goede 2012 22496770	age, smoking, BMI, educational level, parental history of myocardial infarction, alcohol intake, total energy intake, dietary fiber, vit C, beta-careotene, SFA, TFA, MFA, LA, ALA	Qt2	mg/d	57
97	de Goede 2012 22496770	age, smoking, BMI, educational level, parental history of myocardial infarction, alcohol intake, total energy intake, dietary fiber, vit C, beta-careotene, SFA, TFA, MFA, LA, ALA	Qt3	mg/d	107
98	de Goede 2012 22496770	age, smoking, BMI, educational level, parental history of myocardial infarction, alcohol intake, total energy intake, dietary fiber, vit C, beta-careotene, SFA, TFA, MFA, LA, ALA	Qt4	mg/d	nd
99	de Goede 2012 22496770	age, smoking, BMI, educational level, parental history of myocardial infarction, alcohol intake, total energy intake, dietary fiber, vit C, beta-careotene, SFA, TFA, MFA, LA, ALA	Qt1	mg/d	nd
100	de Goede 2012 22496770	age, smoking, BMI, educational level, parental history of myocardial infarction, alcohol intake, total energy intake, dietary fiber, vit C, beta-careotene, SFA, TFA, MFA, LA, ALA	Qt2	mg/d	66
101	de Goede 2012 22496770	age, smoking, BMI, educational level, parental history of myocardial infarction, alcohol intake, total energy intake, dietary fiber, vit C, beta-careotene, SFA, TFA, MFA, LA, ALA	Qt3	mg/d	119
102	de Goede 2012 22496770	age, smoking, BMI, educational level, parental history of myocardial infarction, alcohol intake, total energy intake, dietary fiber, vit C, beta-careotene, SFA, TFA, MFA, LA, ALA	Qt4	mg/d	nd

Row	Study PMID	Quantile median	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
82	Gronroos 2012 22570739	nd	nd	HR	99	nd	17325	Reference group			P trend	0.33
83	Gronroos 2012 22570739	nd	nd	HR	86	nd	15505	0.98	0.73	1.31		
84	Gronroos 2012 22570739	nd	nd	HR	106	nd	17217	1.04	0.78	1.37		
85	Gronroos 2012 22570739	nd	nd	HR	110	nd	17034	1.12	0.85	1.49		
86	de Goede 2013 22633188	Cases: 0.53 (SD = 0.13), Controls: 0.52 (SD = 0.14)	nd	OR	nd	nd	nd	1.02	0.71	1.46		0.41
87	de Goede 2013 22633188	Cases: 1.57 (SD = 1.25), Controls: 1.25 (SD = 0.60)	nd	OR	nd	nd	nd	1.33	0.96	1.84		0.02
88	de Goede 2011 21464993	1	nd	HR	29	4013	nd	Reference group				nd
89	de Goede 2011 21464993	1.2	nd	HR	26	4014	nd	0.63	0.38	1.04		
90	de Goede 2011 21464993	1.3	nd	HR	22	4014	nd	0.45	0.26	0.79		
91	de Goede 2011 21464993	1.5	nd	HR	26	4014	nd	0.56	0.32	0.97		
92	de Goede 2011 21464993	1.9	nd	HR	41	4014	nd	0.7	0.39	1.26		
94	**Subgroup analyses**											
95	de Goede 2012 22496770	36	<57	HR	19	2770	nd	Reference group				
96	de Goede 2012 22496770	77	106	HR	17	2770	nd	0.98	0.5	1.91	P trend	0.21
97	de Goede 2012 22496770	142	188	HR	17	2771	nd	0.98	0.5	1.93		
98	de Goede 2012 22496770	225	>188	HR	11	2770	nd	0.62	0.29	1.35		
99	de Goede 2012 22496770	44	<66	HR	22	2247	nd	Reference group			P trend	0.61
100	de Goede 2012 22496770	89	118	HR	20	2247	nd	0.93	0.5	1.74		
101	de Goede 2012 22496770	157	198	HR	18	2247	nd	0.87	0.46	1.65		
102	de Goede 2012 22496770	241	>199	HR	20	2247	nd	0.85	0.45	1.6		